These are the stories of real patients who chose to share their experiences with radioligand therapy at our institution. They did so voluntarily and with written consent, in the hope that their journey might help others facing a similar path. Their accounts include medical details – laboratory values, imaging results, and treatment responses – because we believe that honest, specific information is more valuable than vague reassurance.
Nonetheless, individual outcomes differ, and nothing on this page should be understood as a promise or prognosis for your own situation. If you would like to find out whether this therapy may be an option for you, we invite you to reach out to us.
The personal accounts quoted in testimonials are published verbatim, retaining the original orthography, syntax, and punctuation.
Complete Remission in Occult Peritoneal Carcinomatosis After Personalized ¹⁶¹Tb/¹⁷⁷Lu-PSMA Therapy, Age 58
How a carefully selected arsenal of isotopes, based on the latest clinical findings, paved the way to complete remission. This case of peritoneal carcinomatosis following robot-assisted Da Vinci prostatectomy illustrates the excellent results that can be achieved with personalized theranostics. Peritoneal carcinomatosis after robot-assisted surgery is not rare and is partly related to the surgical…
3 Cycles of ¹⁷⁷Lu/¹⁶¹Tb-PSMA Therapy Including Brain Metastases – Repeated Complete Remissions, Age 78
The following clinical case illustrates two important aspects of radioligand therapy in prostate cancer treatment. First, it is a highly effective approach capable of transforming the disease from potentially lethal to a manageable chronic condition, with occasional repeated cycles keeping it under control while preserving a good quality of life. Second, Terbium-161 specifically can reach…
Oligometastatic Prostate Cancer, Age 67 – Complete Lymph Node Response After CyberKnife + ¹⁷⁷Lu/¹⁶¹Tb-PSMA Combination
3x ¹⁷⁷Lu-PSMA and 1x ¹⁶¹Tb-PSMA, at 4-Week Intervals Mr. J. Low, 67 years old, was first diagnosed with prostate cancer in February 2011. After multiple prior treatments—including primary external beam radiation, ADT, ARPI, three cycles of immunotherapy, cryotherapy, and irreversible electroporation (IRE)—in 2024 he experienced a slow rise in PSA despite ongoing ADT, suggesting decreasing…
Near-Complete Response After ²²⁵Ac/¹⁷⁷Lu-PSMA Therapy – Skeleton, Liver & Lung Metastases, Age 59
“At the forefront of medicine, with outstanding human care” Mr. T.A., 59 years old, was first diagnosed with prostate cancer (Gleason 7b) in December 2020. Despite intensive pretreatment with irreversible electroporation and electrochemotherapy (IR-ECT) and external beam radiation to the prostate, the disease continued to progress. At the time of referral in December 2024, there…
Stage 4 Prostate Cancer at Age 50 – Full Remission After ¹⁷⁷Lu-PSMA Therapy, PSA from 19 to 0.03
“As of January 2025, I am in full remission and have no evidence of disease.” “At just 50 years old, I was diagnosed with stage 4 prostate cancer in April 2024, which is very rare for someone my age. I then entered the standard of care and was told I would have to do ADT…
Metastatic Prostate Cancer – 7-Year Patient Journey Across Diagnostics and ¹⁷⁷Lu-PSMA Therapy
“Exceptional Care at Minute Medical I have been a patient at Minute Medical GmbH three times over the past seven years, and each experience has been nothing short of outstanding. Dr. Markus Hartenbach, Associate Professor of Nuclear Medicine and a true specialist in Prostate Cancer Theranostics, has consistently demonstrated exceptional expertise, professionalism, and compassionate care.…
PSA from 288 to Below 1 After 3 Sessions of ¹⁷⁷Lu-PSMA Therapy – Kidney Function Restored
“Dr. Hartenbach, his team and treatment literally made a life and death difference. My prostate cancer had spread quickly after a failed immunotherapy. PSA had risen from 60 to 288. Kidney function had been compromised due to lymph involvement.Following the first treatment PSA had dropped to 7 and kidney function bounced back. Following the 3rd,…
No Cancer Detected After 3 Sessions of ¹⁷⁷Lu-PSMA Therapy – Whole-Skeleton Metastases, Age 71
“Getting connected with Dr. Hartenbach was a blessing. Previous treatment did nothing to slow my prostate cancer that had metastasized into my entire skeletal system and some lymph nodes. Three treatments with Minute Medical group and my scan showed no cancer. Even my prostate had no evidence of cancer. From being mostly bed ridden on…
Full Remission After ¹⁷⁷Lu-PSMA Therapy – Chosen Over Chemo, ADT and Radiation, Age 70
Here is a testimonial of one of our patients: “I would like to announce hereby to the world that the small private clinic Minute Medical in Vienna led by Professor Markus Hartenbach, an expert in Nuclear Medicine, is nothing but a giant in helping people in need of medical attention, proving the success of day-to-day…
¹⁷⁷Lu-PSMA Therapy Repeated Across 2 Cycles – Metastatic Prostate Cancer Managed as a Chronic Disease, Age 72
The case illustrates the scientific findings that the radioligand therapy 177Lu-PSMA is safe and effective and can be successfully applied more than once in case of recurrence, moving towards the goal of transforming cancer from lethal into a chronic disease like any other. It also grants the patients considerably better quality of life than the…
Metastatic Prostate Cancer, Age 54 – Remarkable Response After ²²⁵Ac/¹⁷⁷Lu-PSMA Therapy
“This treatment has given me back my life.” Success story after 3 sessions of radioligand PSMA therapy with 1x Actinium-225 & 2x Lutetium-177 Sean Kenny was first diagnosed with prostate cancer in December 2020, when he just turned 51 y.o. Before landing in our clinic, he had undergone multiple treatments, including 6x Docetaxel, antihormonal therapy,…
Complete Remission After ²²⁵Ac-PSMA + ¹⁷⁷Lu-PSMA Therapy – Extensive Bone & Lymph Node Metastases, Age 62
Before the therapy After 3 sessions of PSMA radioligand therapy Control scan a year later
Metastatic Prostate Cancer, Age 72 – 9 Cycles of ¹⁷⁷Lu-PSMA Therapy: Patient Interview
Dr. Hartenbach conducts an interview with a patient about his experience with the radioligand therapy 177Lu-PSMA. The patient A.G., 72 y.o., a molecular biologist himself, was diagnosed with metastatic prostate cancer in September 2018. After the conventional standard-of-care treatment (chemo- and antihormonal therapy) there were still residues of the primary tumour in the prostate, and…
